Clinical Trials Directory

Trials / Completed

CompletedNCT00080197

Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients

An Open-Label Phase II Study of E7070 in Metastatic Breast Cancer Patients Previously Treated With an Anthracycline, a Taxane, and Capecitabine

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
250 (planned)
Sponsor
Eisai Inc. · Industry
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine if E7070 is an efficacious, safe, and tolerable treatment for patients with metastatic breast cancer who have failed, or could not tolerate, prior treatments with an anthracycline, a taxane, and capecitabine.

Conditions

Interventions

TypeNameDescription
DRUGE7070

Timeline

Start date
2004-02-01
Completion
2005-05-01
First posted
2004-03-25
Last updated
2006-10-11

Locations

35 sites across 2 countries: United States, Canada

Source: ClinicalTrials.gov record NCT00080197. Inclusion in this directory is not an endorsement.